Vandetanib Tablets

A drug used to treat medullary thyroid cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Vandetanib blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Vandetanib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Caprelsa and ZD6474.

Vandetanib is approved to treat: Medullary thyroid cancer that cannot be removed by surgery and is locally advanced or has metastasized (spread to other parts of the body). Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015